Press Releases

WAYNE, Pa., July 31, 2019 /PRNewswire/ -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla"), a commercial-stage life sciences company focused on marketing treatments for different types of pain and inflammation, today announced that its second quarter 2019 financial results will be released on Tuesday, August 13, 2019. Following the annou

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2019."Our prostacyclin product franchise, consisting of Remodulin, Tyvaso, and Orenitram, is being used by a larger number of pulmonary arterial hyperten

VANCOUVER and HOUSTON, July 31, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019

BOCA RATON, Fla., July 31, 2019 /PRNewswire/ -- Forbes named CBD as one of its top 10 health trends of 2019.

BOCA RATON, Fla., July 31, 2019 /PRNewswire/ -- Trio Sana, a health and wellness company based in the United Kingdom, partners with farmers in Somaliland, also known as the "

BOCA RATON, Fla., July 31, 2019 /PRNewswire/ -- Peroxfarma, a leading European pharmaceutical company, is bringing an "extra dose of health" to America.Peroxfarma, which decided this year to expand its retail distribution to the United States, offers a wide array of nutritional supplements, such as Epaplus Arthicare, Epaplus

SLOUGH, England and RICHMOND, Va., July 31, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half 2019 results press release and investor supplement are now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at

LUND, Sweden, July 31, 2019  /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide rights from Janssen Biotech Inc. to develop and commercialize the CD40 agonistic antibody, ADC-1013 (JNJ-64457107), its lead tumor-directed immunotherapy candidate, in Phase I development for the treatm

ITASCA, Ill., July 31, 2019 /PRNewswire/ -- In recognition of National Heatstroke Prevention Day on July 31, the National Safety Council and the National Hig

WHIPPANY, N.J., July 30, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).1 The FDA approval is based on the Phase III ARAMIS trial evaluating Nubeqa pl